Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for atrial fibrillation
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Renal Outcomes in Anticoagulated Patients With AtrialFibrillation Lifelong oral anticoagulation, either with warfarin or a non-vitamin K antagonist oral anticoagulant (NOAC), is indicated for stroke prevention in most patients with atrialfibrillation (AF). Emerging evidence suggests that NOACs may be associated with better renal outcomes than warfarin.This study aimed to compare 4 oral anticoagulant agents (apixaban, dabigatran, rivaroxaban, and warfarin) for their effects on 4 renal outcomes
Blood and Clots Quizlet 4: Antithrombotic Therapy for AtrialFibrillation Blood and Clots Quizlet 4: Antithrombotic Therapy for AtrialFibrillation - CanadiEM Blood and Clots Quizlet 4: Antithrombotic Therapy for AtrialFibrillation In , by Eric Tseng November 21, 2017 Hello Blood & Clots/CanadiEM community! Before we post our blog series on thrombosis and bleeding, we encourage you to test your initial knowledge by going through a few brief case scenarios. These cases were originally posted (...) as part of our needs assessment in Fall 2016, and you can find the answers after each question below. The first few quizlets can be found here: , , All the content from the Blood & Clots series can be found . Cheers! -Blood & Clots Editorial Team * * * * * Quizlet #4 You are evaluating a 75 year old man on the medical ward, to organize his discharge home. You notice that his ECG shows atrialfibrillation, rate 88 beats/min. He is well, his BP is 134/76. He has a history of hypertension and colon
Outcomes of Dabigatran and Warfarin for AtrialFibrillation in Contemporary Practice: A Retrospective Cohort Study. Dabigatran (150 mg twice daily) has been associated with lower rates of stroke than warfarin in trials of atrialfibrillation, but large-scale evaluations in clinical practice are limited.To compare incidence of stroke, bleeding, and myocardial infarction in patients receiving dabigatran versus warfarin in practice.Retrospective cohort.National U.S. Food and Drug Administration (...) Sentinel network.Adults with atrialfibrillation initiating dabigatran or warfarin therapy between November 2010 and May 2014.Ischemic stroke, intracranial hemorrhage, extracranial bleeding, and myocardial infarction identified from hospital claims among propensity score-matched patients starting treatment with dabigatran or warfarin.Among 25 289 patients starting dabigatran therapy and 25 289 propensity score-matched patients starting warfarin therapy, those receiving dabigatran did not have
Association of of AtrialFibrillation Clinical Phenotypes With Treatment Patterns and Outcomes: A Multicenter Registry Study Atrialfibrillation (AF) is usually classified on the basis of the disease subtype. However, this characterization does not capture the full heterogeneity of AF, and a data-driven cluster analysis reveals different possible classifications of patients.To characterize patients with AF based on a cluster analysis and to evaluate the association between these phenotypes (...) , treatment, and clinical outcomes.This cluster analysis used data from an observational cohort that included 9749 patients with AF who had been admitted to 174 US sites participating in the Outcomes Registry for Better Informed Treatment of AtrialFibrillation (ORBIT-AF) registry. Data analysis was completed from January 2017 to October 2017.Patients with diagnosed AF who were included in the registry.Composite of major adverse cardiovascular or neurological events and major bleeding, as defined
Usefulness of CHADS2 and CHA2DS2-VASc Scores for Stroke Prediction in Patients With Cancer and AtrialFibrillation Stroke prediction scores have not been validated in patients with cancer and atrialfibrillation (AF). We aimed to identify unique risk factors and evaluate validity of CHADS2 and CHA2DS2-VASc scores to predict risk of stroke and mortality. A retrospective review of all patients with cancer with pre-existing AF presenting from 2008 to 2014 was performed. Outcomes included ischemic
Sex Differences and Similarities in AtrialFibrillation Epidemiology, Risk Factors, and Mortality in Community Cohorts: Results From the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe) Atrialfibrillation (AF) is a common cardiac disease in aging populations with high comorbidity and mortality. Sex differences in AF epidemiology are insufficiently understood.In N=79 793 individuals without AF diagnosis at baseline (median age, 49.6 years; age range, 24.1-97.6
Incidence of Previously Undiagnosed AtrialFibrillation Using Insertable Cardiac Monitors in a High-Risk Population: The REVEAL AF Study In approximately 20% of atrialfibrillation (AF)-related ischemic strokes, stroke is the first clinical manifestation of AF. Strategies are needed to identify and therapeutically address previously undetected AF.To quantify the incidence of AF in patients at high risk for but without previously known AF using an insertable cardiac monitor.This prospective (...) device insertion to first AF episode detection was 123 (41-330) days. Of patients meeting the primary end point, 13 (10.2%) had 1 or more episodes lasting 24 hours or longer, and oral anticoagulation therapy was prescribed for 72 patients (56.3%).The incidence of previously undiagnosed AF may be substantial in patients with risk factors for AF and stroke. Atrialfibrillation would have gone undetected in most patients had monitoring been limited to 30 days. Further trials regarding the value
Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular AtrialFibrillation. Non-vitamin K oral anticoagulants (NOACs) are commonly prescribed with other medications that share metabolic pathways that may increase major bleeding risk.To assess the association between use of NOACs with and without concurrent medications and risk of major bleeding in patients with nonvalvular atrial fibrillation.Retrospective (...) cohort study using data from the Taiwan National Health Insurance database and including 91 330 patients with nonvalvular atrialfibrillation who received at least 1 NOAC prescription of dabigatran, rivaroxaban, or apixaban from January 1, 2012, through December 31, 2016, with final follow-up on December 31, 2016.NOAC with or without concurrent use of atorvastatin; digoxin; verapamil; diltiazem; amiodarone; fluconazole; ketoconazole, itraconazole, voriconazole, or posaconazole; cyclosporine
Implantable cardiac loop recorders for detection of atrialfibrillation following cryptogenic stroke Implantable cardiac loop recorders for detection of atrialfibrillation following cryptogenic stroke Implantable cardiac loop recorders for detection of atrialfibrillation following cryptogenic stroke HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) HAYES, Inc. Implantable cardiac loop recorders for detection of atrialfibrillation following cryptogenic stroke. Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2017 Authors' conclusions Approximately one-third of strokes are cryptogenic (lack an identifiable and treatable cause). Undetected atrialfibrillation (AF) is one suspected cause of cryptogenic stroke. Inability to detect suspected AF after cryptogenic stroke presents a clinical management dilemma. Description of Technology
Left ventricular torsional parameters before and after atrialfibrillation ablation: a velocity vector imaging study Effects of atrialfibrillation (AF) and its ablative treatment on LV torsion have not yet been fully investigated. This study aimed to examine whether AF patterns of LV contraction and its ablative correction can exert a significant impact on LV torsion by velocity vector imaging (VVI).This case-control study conducted in Rajaie Cardiovascular, Medical and Research Center between
Cumulative incidence, risk factors, and management of atrialfibrillation in patients receiving ibrutinib Atrialfibrillation (AF) has been reported in up to 16% of patients taking ibrutinib. Data regarding the management of AF in this patient population are limited, and stroke prevention poses a challenge because of increased risk of bleeding with ibrutinib treatment. Our study sought to describe the incidence of AF in adult patients treated with ibrutinib for a hematologic malignancy, assess
Long-term bleeding risk prediction in 'real world' patients with atrialfibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia AtrialFibrillation Project Risk scores in patients with atrialfibrillation (AF) based on clinical factors alone generally have only modest predictive value for predicting high risk patients that sustain events. Biomarkers might be an attractive prognostic tool to improve bleeding risk prediction. The new ABC-Bleeding score performed better
Comparison of the CHA2DS2-VASc, CHADS2, HAS-BLED, ORBIT, and ATRIA Risk Scores in Predicting Non-Vitamin K Antagonist Oral Anticoagulants-Associated Bleeding in Patients With AtrialFibrillation The increasing adoption of non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrialfibrillation (AF) necessitates a reassessment of bleeding risk scores. Because known risk factors for bleeding are largely the same as for stroke, we hypothesize that stroke risk scores could (...) years], drugs/alcohol concomitantly [1 point each] [HAS-BLED], Outcomes Registry for Better Informed Treatment of AtrialFibrillation [ORBIT], and AnTicoagulation and Risk factors In Atrialfibrillation [ATRIA]) in predicting major and intracranial bleeding. Using a large US commercial insurance database, we identified 39,539 patients with nonvalvular AF who started NOACs between October 1, 2010 and June 30, 2015. The performance of risk scores was compared using C-statistic and net reclassification
Lixiana (edoxaban) - for the prevention of embolism in patients with nonvalvular atrialfibrillation OR treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE. Lixiana (edoxaban) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Lixiana (edoxaban) Conclusion Lixiana (edoxaban) is the fourth Non-vitamin K Oral Anticoagulant (NOAC) in Denmark after Eliques (apixaban), Xarelto (rivaroxaban) and Pradaxa (...) (dabigatran). Lixiana is indicated for the prevention of embolism in patients with nonvalvular atrialfibrillation (NVAF) with one or more risk factors and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE. For either indication, Lixiana is not inferior to warfarin when it comes to preventing embolism and has a statistically significantly lower occurrence of major bleeding. The lower risk of bleeding is particularly evident in comparisons
Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for AtrialFibrillation: The REHEARSE-AF Study Asymptomatic atrialfibrillation (AF) is increasingly common in the aging population and implicated in many ischemic strokes. Earlier identification of AF with appropriate anticoagulation may decrease stroke morbidity and mortality.We conducted a randomized controlled trial of AF screening using an AliveCor Kardia monitor attached to a WiFi-enabled iPod to obtain
Bleeding-related hospital admissions and 30-day readmissions in patients with non-valvular atrialfibrillation treated with dabigatran versus warfarin Essentials Bleeding is a common cause of hospital admission and readmission in oral anticoagulant users. Patients with dabigatran and warfarin were included to assess hospital admission risk. Dabigatran users had a higher risk of 30-day readmission with bleeding than warfarin users. Close monitoring following hospital discharge for dabigatran (...) . warfarin in patients with non-valvular atrialfibrillation (NVAF). Methods This was a retrospective cohort study using a population-wide database managed by the Hong Kong Hospital Authority. Patients newly diagnosed with NVAF from 2010 through to 2014 and prescribed dabigatran or warfarin were 1:1 matched by propensity score. The incidence rate of hospital admission with bleeding (a composite of gastrointestinal bleeding, intracranial hemorrhage and bleeding at other sites) was assessed. Results Among
Impact of creatinine clearance on outcomes in patients with non-valvular atrialfibrillation: a subanalysis of the J-RHYTHM Registry To clarify the influence of renal function on adverse outcomes in patients with non-valvular atrialfibrillation (NVAF), a post hoc analysis of the J-RHYTHM Registry was performed.A consecutive series of outpatients with atrialfibrillation (AF) were enrolled from 158 institutions and followed for 2 years or until the occurrence of an event. Among 7406 patients
Dual Antithrombotic Therapy with Dabigatran after PCI in AtrialFibrillation. Triple antithrombotic therapy with warfarin plus two antiplatelet agents is the standard of care after percutaneous coronary intervention (PCI) for patients with atrialfibrillation, but this therapy is associated with a high risk of bleeding.In this multicenter trial, we randomly assigned 2725 patients with atrialfibrillation who had undergone PCI to triple therapy with warfarin plus a P2Y12 inhibitor (clopidogrel (...) ; 95% CI, 0.84 to 1.29; P=0.005 for noninferiority). The rate of serious adverse events did not differ significantly among the groups.Among patients with atrialfibrillation who had undergone PCI, the risk of bleeding was lower among those who received dual therapy with dabigatran and a P2Y12 inhibitor than among those who received triple therapy with warfarin, a P2Y12 inhibitor, and aspirin. Dual therapy was noninferior to triple therapy with respect to the risk of thromboembolic events. (Funded